🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in India / NCT03141021
Recruiting Observational

Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors

NCT03141021 · tracked via the Priya Life Science India tracker
Sponsor
Washington University School of Medicine
Phase
Observational
Started
2017-04-28
Last updated
2026-03-09

Condition(s) studied

Malignant Peripheral Nerve Sheath Tumors

Study summary

First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumor (MPNST) and precursor lesions (e.g., atypical or nodular plexiform neurofibromas). A worldwide database will be established, collecting, in a standardized manner, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from centers worldwide with expertise in these NF1-related cancers. Although retrospective in nature, the resulting data from this registry may reveal previously unanticipated patterns, similar to the INFACT effort outcome. This registry would then allow the acquisition of data associated with MPNST biospecimens collected under associated banks (frozen or paraffin-embedded, germline (or normal tissue DNA) samples, and any previously somatic whole-exome or whole-genome sequencing data for aggregate analyses). Second, the investigators plan to co-register patients to institutional banks in order to prospectively collect MPNST samples for analysis. These patients will be consented in order to collect the above information and for banking of tumor tissue and future studies that include genomic characterization of the tumors.

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion Criteria and Exclusion Criteria: -Any patient diagnosed with an MPNST is eligible for enrollment to this registry provided s/he consents to participate (or consent form his/her parent or legal guardian or legally authorized representative is obtained).

Primary outcome measure(s)

Trial sites (13)

FacilityCityRegionStatus
Moffitt Cancer Center Tampa Florida Completed
Johns Hopkins Baltimore Maryland Recruiting
National Institutes of Health (NIH) Bethesda Maryland Not Yet Recruiting
Dana Farber Cancer Institute Boston Massachusetts Withdrawn
University of Minnesota Minneapolis Minnesota Withdrawn
Washington University School of Medicine St Louis Missouri Recruiting
Memorial Sloan Kettering Cancer Center New York New York Not Yet Recruiting
Lifespan Providence Rhode Island Completed
University of Utah Salt Lake City Utah Completed
Mount Sinai Toronto Ontario Recruiting
Global Gene Corporation Mumbai India Completed
Nagoya University Hospital Nagoya Showa Ward Recruiting
Royal National Orthopedic Hospital London United Kingdom Terminated
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03141021 on ClinicalTrials.gov ↗ ← All trials in India